---
aliases: [AI in biopharma, AI-designed drugs, AI pharma, TechBio]
---
#concept #ai #biopharma #drugdiscovery

**AI drug discovery** — AI transforming pharma R&D. $1.4B market. First AI drug (Rentosertib) in Phase 2. 67 AI candidates in clinic.

---

## Market overview

| Metric | Value |
|--------|-------|
| Market size (2025) | **$1.9B** |
| Projected (2034) | $16.5B |
| CAGR | 27% |
| AI deals (2025) | 120 (23% of all since 2017) |
| Drugs in clinic | **67** (vs 3 in 2016) |

---

## AI impact on drug discovery

| Metric | Traditional | AI-enabled |
|--------|-------------|------------|
| Phase 1 success rate | ~40% | **80-90%** |
| Timeline reduction | — | 25-50% shorter |
| Cost reduction | $2.6B avg | Significant savings |
| Target identification | Years | Months |

---

## First AI-designed drugs

### Rentosertib (Insilico Medicine)

| Metric | Value |
|--------|-------|
| Target | TNIK inhibitor |
| Indication | Idiopathic pulmonary fibrosis (IPF) |
| Status | **Phase 2a completed** |
| Result | Met primary endpoint, dose-dependent FVC improvement |
| Significance | First AI-discovered drug to show Phase 2 efficacy |

**Nature Medicine (May 2025):** First clinical proof-of-concept for AI drug discovery.

### Other AI candidates

| Drug | Company | Status |
|------|---------|--------|
| Zasocitinib (TAK-279) | Nimbus/Takeda | **Phase 3** |
| REC-994 | Recursion | Discontinued (May 2025) |
| Isomorphic candidates | Isomorphic Labs | Entering trials |

---

## Key platforms

| Company | Platform | Strength |
|---------|----------|----------|
| [[Recursion]] | Recursion OS | Biology, 60PB data |
| [[Insilico Medicine]] | Pharma.AI | Chemistry, generative AI |
| [[Isomorphic Labs]] | AlphaFold 3 | Protein structure |
| Schrödinger | Physics-based | Molecular simulation |
| BenevolentAI | Knowledge graph | Target discovery |

---

## Major deals (2024-2025)

| Deal | Partners | Value |
|------|----------|-------|
| [[Isomorphic Labs]] | Novartis + Lilly | **$3B** |
| [[Insilico Medicine]] | Sanofi | $1.2B |
| Monte Rosa | Novartis | $5.76B (Sep 2025) |
| Recursion | Roche-Genentech | Multi-program |
| Recursion | Bayer | Oncology |

---

## FDA milestones

| Date | Milestone |
|------|-----------|
| Dec 2025 | First AI drug development tool qualified (AIM-NASH) |
| 2025 | 67 AI-discovered drugs in clinical trials |
| TBD | First AI-discovered drug approval (pending) |

---

## AI applications by stage

| Stage | AI Application |
|-------|----------------|
| Target discovery | Knowledge graphs, literature mining |
| Hit identification | Virtual screening, generative chemistry |
| Lead optimization | ADMET prediction, molecular design |
| Preclinical | Toxicity prediction, animal model selection |
| Clinical | Patient stratification, trial design |
| Manufacturing | Process optimization |

---

## AI in pathology

| Company | Product | Function |
|---------|---------|----------|
| [[Tempus]] | David, Paige | Digital pathology, clinical AI |
| PathAI | AIM-NASH | FDA-qualified MASH assessment |
| Owkin | MOSAIC | Tumor microenvironment |

**FDA first:** AIM-NASH qualified Dec 2025 for MASH clinical trials.

---

## Investment landscape

| Investor type | Activity |
|---------------|----------|
| Big Pharma | Platform deals ($1B+) |
| VC | $26B in biopharma (2024) |
| Strategics | M&A (Recursion-Exscientia) |

---

## Challenges

| Challenge | Detail |
|-----------|--------|
| No approved drug yet | Validation pending |
| Data quality | Garbage in, garbage out |
| Interpretability | Black box concerns |
| Biology complexity | AI can't solve everything |
| Clinical translation | Preclinical ≠ human efficacy |

---

## Investment case

**Bull:**
- 80-90% Phase 1 success vs 40%
- Timeline/cost reduction
- Platform deals validating technology
- First Phase 2 success (Rentosertib)

**Bear:**
- No approved drug yet
- REC-994 failure shows limits
- Hype cycle risk
- Big Pharma building in-house

---

## Related

- [[Biopharma]] — sector
- [[Recursion]] — largest AI biotech
- [[Insilico Medicine]] — first Phase 2 success
- [[Isomorphic Labs]] — AlphaFold spinout
- [[Tempus]] — AI diagnostics
- [[Google DeepMind]] — AlphaFold creator

---

## Sources

- [Nature Medicine: Rentosertib Phase 2](https://www.nature.com/articles/s41591-025-03743-2)
- [FDA: First AI drug tool](https://www.fda.gov/drugs/drug-safety-and-availability/fda-qualifies-first-ai-drug-development-tool-will-be-used-mash-clinical-trials)
- [McKinsey: Biopharma AI](https://www.mckinsey.com/industries/life-sciences/our-insights/)

*Created 2026-01-09*
